AKRO vs. CRVS

Last updated Apr 2, 2026

Compare and contrast key facts about Akero Therapeutics, Inc. (AKRO) and Corvus Pharmaceuticals, Inc. (CRVS).

Performance

AKRO vs. CRVS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Akero Therapeutics, Inc. (AKRO) and Corvus Pharmaceuticals, Inc. (CRVS). The values are adjusted to include any dividend payments, if applicable.

AKRO vs. CRVS - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019
AKRO Akero Therapeutics, Inc.	0.00%	96.44%	19.14%	-57.39%	159.10%	-18.02%	16.24%	21.15%
CRVS Corvus Pharmaceuticals, Inc.	87.40%	43.93%	203.98%	107.06%	-64.73%	-32.30%	-34.56%	50.69%

Fundamentals

Market Cap AKRO : $4.48B CRVS : $1.15B
EPS AKRO : -$3.58 CRVS : -$0.19
PB Ratio AKRO : 4.68 CRVS : 18.80
Total Revenue (TTM) AKRO : $0.00 CRVS : $0.00
Gross Profit (TTM) AKRO : $0.00 CRVS : $0.00
EBITDA (TTM) AKRO : -$288.18M CRVS : -$42.97M

Returns By Period

AKRO

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

CRVS

• 1D: -1.37%
• 1M: -19.34%
• YTD: 87.40%
• 6M: 98.76%
• 1Y: 355.21%
• 3Y*: 151.23%
• 5Y*: 35.66%
• 10Y*: 0.13%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

AKRO vs. CRVS — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CRVS

CRVS Risk / Return Rank: 96
CRVS Sharpe Ratio Rank: 90
CRVS Sortino Ratio Rank: 99
CRVS Omega Ratio Rank: 97
CRVS Calmar Ratio Rank: 97
CRVS Martin Ratio Rank: 97

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

AKRO vs. CRVS - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Akero Therapeutics, Inc. (AKRO) and Corvus Pharmaceuticals, Inc. (CRVS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	AKRO	CRVS	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	—	1.97	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	0.27	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.00	—
Sharpe Ratio (All Time) Calculated using the full available price history	—	0.00	—

Correlation

The correlation between AKRO and CRVS is 0.22, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

AKRO vs. CRVS - Dividend Comparison

Neither AKRO nor CRVS has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

Drawdown Indicators

	AKRO	CRVS	Difference
Max Drawdown Largest peak-to-trough decline	—	-96.97%	—
Max Drawdown (1Y) Largest decline over 1 year	—	-48.47%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-92.40%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-96.97%	—
Current Drawdown Current decline from peak	—	-43.46%	—
Average Drawdown Average peak-to-trough decline	—	-69.78%	—
Ulcer Index Depth and duration of drawdowns from previous peaks	—	17.06%	—

Volatility

Volatility by Period

	AKRO	CRVS	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	22.80%	—
Volatility (6M) Calculated over the trailing 6-month period	—	109.45%	—
Volatility (1Y) Calculated over the trailing 1-year period	—	182.13%	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	—	130.57%	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	—	110.95%	—

Financials